Heart Failure | Access and Reimbursement | Chronic Heart Failure | US | 2016
The chronic heart failure therapy market is crowded and dominated by generics. In 2015 in the United States, the first new branded agents in more than 15 years entered that market. Using primary research from U.S. cardiologists, primary care physicians, and managed care organization medical/pharmacy directors, this content examines market access factors in the United States. Understanding the interaction between payers and physicians, including the impact of reimbursement decisions on the prescribing and uptake of therapies at the brand level, will help unravel treatment drivers in this indication.
Related Market Assessment Reports
Report
Acute Coronary Syndrome – Unmet Need – Unmet Need – Acute Coronary Syndrome: Secondary Prevention, on Top of Statin Treatment (US/EU)
This report covers the 12-month post-hospital management of secondary prevention in ACS patients. Reducing cardiovascular (CV) residual risk and achieving guideline-recommended LDL-C targets…
Report
Multiple Sclerosis – Unmet Need – Unmet Need – Multiple Sclerosis: Nonrelapsing Secondary-Progressive Multiple Sclerosis (US/EU)
No treatments are approved for nonrelapsing secondary-progressive multiple sclerosis (nrSP-MS), an MS disease course in which physical disability accumulates in the absence of superimposed relapses…
Report
Myasthenia Gravis – Current Treatment – Treatment Algorithms: Claims Data Analysis – Myasthenia Gravis (US)
Myasthenia gravis (MG) is a rare neuromuscular disorder caused by specific autoantibodies at the neuromuscular junction; in most patients, these autoantibodies target acetylcholine receptors. MG is…
